Ginkgo for antidepressant sexual side effects: two blinded trials found no advantage
Early enthusiasm for ginkgo and antidepressant-related sexual dysfunction was not reproduced in two randomized placebo-controlled trials.

Two small blinded trials did not find ginkgo better than placebo for antidepressant-associated sexual dysfunction, and medicine changes require clinical guidance.
A medication side effect is a specific problem
Sexual difficulties associated with antidepressants can involve desire, arousal, erections, orgasm, or ejaculation. They also overlap with symptoms of depression and anxiety. That makes the treatment question more complicated than a general male-enhancement claim. A useful trial must track mood, medication, baseline sexual function, and the specific domains affected.
Ginkgo biloba gained attention after uncontrolled reports suggested benefit. Uncontrolled improvement can reflect expectation, changing mood, adaptation to medication, relationship factors, or normal variation. Randomized placebo-controlled trials are needed to separate those influences from an extract effect.

A double-blind trial did not replicate benefit
One randomized double-blind study assigned 37 antidepressant users to ginkgo or placebo for two months. Both groups improved on parts of sexual-function assessment, but there was no statistically significant advantage for ginkgo at weeks two, four, or eight. The authors highlighted the importance of placebo effects when studying sexual outcomes.
The study was modest, so it cannot exclude every possible effect or identify a small responsive subgroup. It does directly challenge a broad claim that ginkgo reliably reverses antidepressant sexual side effects. Improvement from baseline in both groups should not be reported as proof that the active supplement worked.
A triple-blind trial was also negative
A second randomized trial blinded participants, investigators, and the statistician. Twenty-four people with antidepressant-associated sexual impairment entered the study, and fewer completed the full 12 weeks. Some individuals in both groups had striking responses, but the groups did not differ significantly and side effects were similar.
Individual improvement is not the same as a treatment effect. When equally dramatic changes occur with placebo, testimonials cannot determine the cause. The small sample creates uncertainty, but two blinded trials failing to show an advantage is materially different from having no controlled evidence at all.
Safety and medication management come first
NCCIH says ginkgo leaf extract can cause headache, dizziness, and gastrointestinal symptoms and may increase bleeding risk with anticoagulant medicines. It can interact with other drugs. The safety of a specific standardized extract also should not be confused with fresh seeds or crude plant material, which can be toxic.
Do not stop, reduce, or switch an antidepressant to test a supplement without the prescriber's help. Discuss the timing and type of sexual symptoms, mood control, other medicines, and evidence-based management options. Current trials do not support presenting ginkgo as a dependable solution, and its interaction profile makes unsupervised add-on use a poor experiment.

Measure the side effect before trying to solve it
A useful clinical discussion identifies when the symptom began, the antidepressant and dose at that time, whether mood symptoms were already affecting sexual function, and which domain changed. Desire, erection, lubrication, delayed orgasm, and genital sensation may require different management. A vague “performance” score can hide the problem that matters most to the patient.
Keeping a brief timeline can help distinguish a medication effect from an underlying condition or another drug. It also prevents an ineffective supplement trial from delaying better-supported options. Because maintaining mental-health stability is important, any adjustment should balance sexual adverse effects against relapse risk. A product page cannot make that individualized tradeoff, and two negative blinded ginkgo trials give no reason to expect a reliable workaround.
The standardized extract also matters. Trial results from a defined leaf extract do not support tea, tincture, whole plant, or seed products. Ginkgo seeds have a different safety profile, and NCCIH specifically warns that fresh seeds are toxic. A label should identify the plant part and extract rather than relying on a leaf image. Even a product matching the research material would still face the central problem: controlled trials did not show superiority to placebo. A systematic review reached the same practical conclusion for antidepressant users, reinforcing the randomized findings rather than the reputation created by uncontrolled reports.
A null trial is still useful evidence
Negative controlled findings prevent consumers and clinicians from relying indefinitely on early enthusiasm. They also redirect research toward better-defined management strategies. Ginkgo could still be studied in a different population or formulation, but that possibility is not evidence of current benefit. The burden remains on a new trial to show an advantage rather than on readers to disprove every hypothetical subgroup.
Sources & further reading
This article provides educational information. Ask a qualified clinician or pharmacist about your symptoms, medical conditions, medicines and supplement interactions.